Longterm Survial after Re-challenge with Radiumdichlorid – a Case Report

Introduction 

The life-prolonging effects of Radium-223-dichlorid (²²³RaCl₂) have been shown in the ALSYMCA trial in 2013 [1] in patients with advanced prostate cancer and dominating bone metastases. Consequently, it was approved by the US Food and Drug Administration (FDA) as well as the European Medicines Agency (EMA). Typical initial treatment consists of 6 cycles ²²³RaCl₂ given in intervals of 4 weeks.

As often relapse of the disease can be observed in the treated patients after some time, soon the repeated application of ²²³RaCl₂ was discussed and analyzed in prospective trials [2]. While toxicity of repeated application of ²²³RaCl₂ was found to be acceptable and no major issue in most cases, the outcome was shown to be very variable. Therefore, we want to report on one patient in whom bone metastases of an advanced, castration-resistant prostate carcinoma could be stabilized for nearly two years with repeated treatment with ²²³RaCl₂.

Publication History

Article published online:
18 February 2021

• References

• 1 Parker C, Nilsson S, Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223
• 2 Sartor O, Heinrich D, Mariados N. et al. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. Ann Oncol 2017; 28: 2464-2471